REGENERON PHARMACEUTICALSREGN
ASignal's systematic analysis rates REGN as Bullish.
Reflects the latest available analysis · analyzed Sep 15, 2026
The case on REGN
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong free cash flow of $3.07B indicating high-quality earnings
- Low debt-to-equity ratio of 0.09x signaling strong financial health
- High operating margin of 33.11% reflecting pricing power and efficiency
- Forward P/E of 12.84x below current P/E, suggesting earnings growth expectations
- Positive revenue growth year-over-year at 16.70%
- High cash reserves with $7.99B in total cash
- Negative price momentum indicating short-term downtrend
- MACD below signal line with negative histogram, showing weakening bullish momentum
- Earnings growth declining YoY by 4.50%
- No Reddit mentions, indicating low retail investor sentiment visibility
Peers
Clustered with REGN by analysis-profile similarity.
See the full verdict on REGN
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes REGN
Most investors never get a second opinion, let alone several. ASignal runs REGN past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.